Andrew Hykes - Nov 16, 2023 Form 4 Insider Report for Inari Medical, Inc. (NARI)

Role
President and CEO, Director
Signature
/s/ Shannon Trevino, attorney-in-fact for Andrew Hykes
Stock symbol
NARI
Transactions as of
Nov 16, 2023
Transactions value $
-$2,240,277
Form type
4
Date filed
11/17/2023, 07:17 PM
Previous filing
Oct 3, 2023
Next filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Sale -$1.25M -21K -4.45% $59.53 451K Nov 16, 2023 Direct F1, F2
transaction NARI Common Stock Sale -$988K -16.4K -3.64% $60.20 435K Nov 16, 2023 Direct F1, F3
holding NARI Common Stock 1.55K Nov 16, 2023 By Child 1
holding NARI Common Stock 1.55K Nov 16, 2023 By Child 2
holding NARI Common Stock 1.55K Nov 16, 2023 By Child 3
holding NARI Common Stock 1K Nov 16, 2023 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $58.93 to $59.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $59.93 to $60.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.